Sapience Investments LLC Boosts Stake in Integra Lifesciences Holdings Corp (NASDAQ:IART)

Sapience Investments LLC grew its stake in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 23.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 163,810 shares of the life sciences company’s stock after buying an additional 31,000 shares during the period. Sapience Investments LLC owned 0.19% of Integra Lifesciences worth $9,149,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Municipal Employees Retirement System of Michigan raised its holdings in shares of Integra Lifesciences by 1.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 13,080 shares of the life sciences company’s stock worth $731,000 after buying an additional 190 shares during the last quarter. Zions Bancorporation N.A. raised its holdings in shares of Integra Lifesciences by 5.9% during the second quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock worth $243,000 after purchasing an additional 242 shares during the last quarter. LPL Financial LLC raised its holdings in shares of Integra Lifesciences by 4.4% during the second quarter. LPL Financial LLC now owns 5,754 shares of the life sciences company’s stock worth $319,000 after purchasing an additional 242 shares during the last quarter. Advisor Group Inc. raised its holdings in shares of Integra Lifesciences by 0.9% during the first quarter. Advisor Group Inc. now owns 30,842 shares of the life sciences company’s stock worth $1,719,000 after purchasing an additional 282 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund raised its holdings in shares of Integra Lifesciences by 1.4% during the second quarter. Oregon Public Employees Retirement Fund now owns 28,654 shares of the life sciences company’s stock worth $1,600,000 after purchasing an additional 404 shares during the last quarter. 81.83% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently issued reports on IART shares. Oppenheimer raised their target price on shares of Integra Lifesciences from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. BTIG Research set a $70.00 target price on shares of Integra Lifesciences and gave the stock a “buy” rating in a report on Wednesday, July 24th. BidaskClub cut shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 28th. Zacks Investment Research raised shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 target price for the company in a report on Monday, September 2nd. Finally, Royal Bank of Canada set a $66.00 target price on shares of Integra Lifesciences and gave the stock a “hold” rating in a report on Friday, July 26th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $62.67.

IART stock traded down $0.27 during midday trading on Monday, hitting $61.13. 10,520 shares of the stock traded hands, compared to its average volume of 497,815. The firm has a market cap of $5.29 billion, a P/E ratio of 25.22, a PEG ratio of 1.94 and a beta of 1.10. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.76 and a quick ratio of 1.82. The stock’s fifty day simple moving average is $61.45 and its 200-day simple moving average is $55.12. Integra Lifesciences Holdings Corp has a 1-year low of $42.14 and a 1-year high of $66.41.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, July 24th. The life sciences company reported $0.73 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.08. The company had revenue of $383.60 million for the quarter, compared to analyst estimates of $373.29 million. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business earned $0.60 earnings per share. On average, research analysts predict that Integra Lifesciences Holdings Corp will post 2.73 earnings per share for the current year.

In related news, COO Glenn Coleman sold 3,650 shares of the firm’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $55.00, for a total transaction of $200,750.00. Following the sale, the chief operating officer now owns 25,160 shares in the company, valued at $1,383,800. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Richard E. Caruso sold 80,000 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $61.77, for a total transaction of $4,941,600.00. Following the sale, the insider now owns 134,134 shares in the company, valued at approximately $8,285,457.18. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 371,571 shares of company stock worth $22,617,425. 4.50% of the stock is owned by company insiders.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

See Also: Buy Rating

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.